Although we lack direct evidece of serum B7-H4 for predicting prognosis of ICC patients, we believe that B7-H4 may appear as a novel marker in predicting the prognosis and a potential therapeutic target for those patients. This evidence concerns the gene VTCN1 and intrahepatic cholangiocarcinoma.